Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARYA Sciences Acquisition Corp VARYE · Entity 137308 | Director | July 12, 2021 | July 13, 2021 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Director | May 18, 2022 | May 28, 2022 |
| Relay Therapeutics, Inc.RLAY · Entity 4044 | Director · President and CEO | October 07, 2026 | October 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARYA Sciences Acquisition Corp V
Report date July 12, 2021 · Filed July 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-257335) under the heading "Description of Securities--Founder Shares", the Class B ordinary shares, par value $0.0001 per share, will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination on a one-for-one basis, subject to adjustment for stock splits, stock dividends, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
PROTHENA CORP PUBLIC LTD CO
Report date May 18, 2022 · Filed May 28, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.60 · Expires 2032-05-18 | Direct | 15,000 |
Reported balance
After 2022-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-18 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date.
Relay Therapeutics, Inc.
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 471,301 |
Reported balance
After 2026-10-07 transaction · row 1
1 source rowRow 1 · 2026-10-07 · Sale · Disposed 48,199 · Balance 471,301 F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025. F2: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy The Patel Family Irrevocable Trust of 2019 | 199,548 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 199,548 F3: These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy The SSP Irrevocable Trust of 2020 | 687,355 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 687,355 F3: These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2023 Filed Jan 20, 2023 01:33 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 28,000 | $5.04 | $141,120.00 |
DisclosureSEC source: 0001209191-23-004127 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,825 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · derivative · entry 11 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,779 Underlying: Common Stock · 9,825 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F5 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,175 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · derivative · entry 10 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,175 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F4 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 9,825 | $20.00 | $196,500.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · nonDerivative · entry 6 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 9,825 | $5.04 | $49,518.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · nonDerivative · entry 5 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 18,175 | $20.00 | $363,500.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| November 10, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 18,175 | $4.12 | $74,881.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · derivative · entry 9 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F4 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $20.18 | $282,520.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.00 to $20.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 08, 2022 Filed Nov 10, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-056427 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| October 28, 2022 Filed Jan 31, 2023 21:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GiftCommon Stock | 254,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005702 · doc5.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By The SSP Irrevocable Trust of 2020 Disclosed balance after: 687,355 F1 · ownership.nature: These shares are held in an irrevocable trust for the benefit of the reporting person's family members. An independent trustee is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| October 28, 2022 Filed Jan 31, 2023 21:27 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GiftCommon Stock | 254,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-005702 · doc5.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · derivative · entry 11 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $20.58 | $288,120.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · nonDerivative · entry 6 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $20.28 to $20.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · nonDerivative · entry 5 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · derivative · entry 10 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $21.18 | $296,520.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.78 to $21.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 12, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · derivative · entry 9 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $21.36 | $299,040.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.76 to $21.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| October 11, 2022 Filed Oct 13, 2022 22:09 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-053597 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · derivative · entry 11 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $23.80 | $333,200.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · nonDerivative · entry 6 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F4 · price: This transaction was executed in multiple trades at prices ranging from $23.36 to $24.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · nonDerivative · entry 5 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · derivative · entry 10 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $23.47 | $328,580.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.89 to $24.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 14, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| September 13, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · derivative · entry 9 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| September 13, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $25.45 | $356,300.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $24.99 to $26.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 13, 2022 Filed Sep 16, 2022 01:02 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-050182 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022. Read SEC document |
| June 30, 2022 Filed Jul 8, 2022 20:22 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 814 | $14.24 | $11,591.36 |
DisclosureSEC source: 0001209191-22-041639 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,554 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2022. Read SEC document |
| May 18, 2022 Filed May 28, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $25.60 | $0.00 |
DisclosureSEC source: 0001140361-22-021109 · form4.xml · derivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2023 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · derivative · entry 15 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 704,604 Underlying: Common Stock · 14,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F7 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · derivative · entry 14 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $30.51 | $427,140.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 10 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,740 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $32.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $5.04 | $70,560.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 9 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $30.51 | $427,140.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 8 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,740 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F5 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $32.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 14, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 7 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · derivative · entry 13 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 718,604 Underlying: Common Stock · 14,000 shares Expires 2029-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F7 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · derivative · entry 12 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,175 Underlying: Common Stock · 14,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $31.94 | $447,160.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 6 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,740 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F4 · price: This transaction was executed in multiple trades at prices ranging from $31.43 to $32.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $5.04 | $70,560.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 5 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 14,000 | $31.96 | $447,440.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 4 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,740 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.48 to $32.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 14,000 | $4.12 | $57,680.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 3 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. Read SEC document |
| April 12, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · derivative · entry 11 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,175 Underlying: Common Stock · 28,000 shares Expires 2028-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F6 · derivative.exercise_date: The shares underlying this option shall vest in sixteen (16) equal quarterly installments after March 23, 2018, subject to the reporting person's continued employment through each applicable vesting date. Read SEC document |
| April 12, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | SaleCommon Stock | 28,000 | $31.80 | $890,400.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 2 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,740 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.89 to $32.58. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 12, 2022 Filed Apr 15, 2022 01:20 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | Exercise / conversionCommon Stock | 28,000 | $4.12 | $115,360.00 |
DisclosureSEC source: 0001209191-22-024487 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2021. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 22:25 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantStock Option (Right to Buy) · Derivative | 527,140 | $0.00 Strike: $20.38 | $0.00 |
DisclosureSEC source: 0001209191-22-005675 · doc4.xml · derivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,140 Underlying: Common Stock · 527,140 shares Expires 2032-01-26 F1 · derivative.exercise_date: The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 27, 2022, subject to the reporting person's continued service with the Issuer through each vesting date. Read SEC document |
| December 31, 2021 Filed Jan 7, 2022 22:13 UTC | Relay Therapeutics, Inc. RLAY · Entity 4044 | GrantCommon Stock | 658 | $26.10 | $17,173.80 |
DisclosureSEC source: 0001209191-22-002465 · doc4.xml · nonDerivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,740 F1 · kind: The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. F2 · price: In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on December 31, 2021. Read SEC document |
| May 19, 2021 Filed May 21, 2021 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $23.97 | $0.00 |
DisclosureSEC source: 0001567619-21-010961 · doc1.xml · derivative · entry 1 Patel Sanjiv · CIK 0001816210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2031-05-19 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 33 1/3% of the total number of shares subject to the option on the first anniversary of the grant date, 33 1/3% on the second anniversary of the grant date, and the remaining 33 1/3% on the earlier of the third anniversary of the grant date or the day of the annual general meeting in 2024 of the Issuer's shareholders, assuming continuous services as a director until each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.